Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > CRNX Crinetics > Detailed Quotes

CRNX Crinetics

17.950
-0.490-2.66%
Close 10/06 16:00 ET
17.9500.0000.00%
Post Mkt Price 10/06 16:01 ET
High
18.390
Open
18.250
Turnover
4.62M
Low
17.890
Pre Close
18.440
Volume
256.07K
Market Cap
964.86M
P/E(TTM)
Loss
52wk High
28.950
Shares
53.75M
P/E(Static)
Loss
52wk Low
15.910
Float Cap
720.16M
Bid/Ask %
33.33%
Historical High
42.000
Shs Float
40.12M
Volume Ratio
1.25
Historical Low
10.630
Dividend TTM
--
Div Yield TTM
--
P/B
2.50
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.64%
Amplitude
2.71%
Avg Price
18.025
Lot Size
1
Float Cap
720.16M
Bid/Ask %
33.33%
Historical High
42.000
Shs Float
40.12M
Volume Ratio
1.25
Historical Low
10.630
Dividend TTM
--
P/B
2.50
Dividend LFY
--
Turnover Ratio
0.64%
Amplitude
2.71%
Avg Price
18.025
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
CEO: Dr. R. Scott Struthers, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...